Search

Victor N Sakran

Examiner (ID: 15805)

Most Active Art Unit
3507
Art Unit(s)
3507, 3505, 3677, 3626, 2899
Total Applications
3429
Issued Applications
3196
Pending Applications
92
Abandoned Applications
141

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17719048 [patent_doc_number] => 20220211767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => ENHANCEMENT OF FIBROBLAST THERAPEUTIC ACTIVITY BY T CELL MODULATION [patent_app_type] => utility [patent_app_number] => 17/594730 [patent_app_country] => US [patent_app_date] => 2020-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594730 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/594730
ENHANCEMENT OF FIBROBLAST THERAPEUTIC ACTIVITY BY T CELL MODULATION Apr 26, 2020 Pending
Array ( [id] => 16397305 [patent_doc_number] => 20200338163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR [patent_app_type] => utility [patent_app_number] => 16/858154 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16363 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858154 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/858154
Methods for cardiac tissue repair with compositions comprising CTGF Apr 23, 2020 Issued
Array ( [id] => 16375113 [patent_doc_number] => 20200323955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION [patent_app_type] => utility [patent_app_number] => 16/851287 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851287 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/851287
Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor Apr 16, 2020 Issued
Array ( [id] => 16362445 [patent_doc_number] => 20200319196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 16/838711 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16838711 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/838711
USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE Apr 1, 2020 Abandoned
Array ( [id] => 17281694 [patent_doc_number] => 11198714 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Synthetic truncated norrin protein [patent_app_type] => utility [patent_app_number] => 16/829283 [patent_app_country] => US [patent_app_date] => 2020-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 22 [patent_no_of_words] => 11930 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16829283 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/829283
Synthetic truncated norrin protein Mar 24, 2020 Issued
Array ( [id] => 17713510 [patent_doc_number] => 11377493 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Method for treating cancer with c-kit antibodies [patent_app_type] => utility [patent_app_number] => 16/818149 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 29069 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818149 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/818149
Method for treating cancer with c-kit antibodies Mar 12, 2020 Issued
Array ( [id] => 19150164 [patent_doc_number] => 11975054 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-07 [patent_title] => Nucleic acid molecules encoding clostridium histolyticum collagenase I and methods of producing the same [patent_app_type] => utility [patent_app_number] => 16/816097 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 16584 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16816097 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/816097
Nucleic acid molecules encoding clostridium histolyticum collagenase I and methods of producing the same Mar 10, 2020 Issued
Array ( [id] => 16267352 [patent_doc_number] => 20200268839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => COMPOSITION FOR TREATING PULMONARY FIBROSIS AND EMPHYSEMA AND THERAPEUTIC METHOD USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/798953 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4963 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798953 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/798953
COMPOSITION FOR TREATING PULMONARY FIBROSIS AND EMPHYSEMA AND THERAPEUTIC METHOD USING THE SAME Feb 23, 2020 Abandoned
Array ( [id] => 17378143 [patent_doc_number] => 11236140 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Interleukin 15 fusion protein for tumor targeting therapy [patent_app_type] => utility [patent_app_number] => 16/798269 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 15 [patent_no_of_words] => 5584 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798269 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/798269
Interleukin 15 fusion protein for tumor targeting therapy Feb 20, 2020 Issued
Array ( [id] => 16297819 [patent_doc_number] => 20200283542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 16/793643 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16793643 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/793643
ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA Feb 17, 2020 Abandoned
Array ( [id] => 16704365 [patent_doc_number] => 10954285 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Humanized anti-PACAP antibodies [patent_app_type] => utility [patent_app_number] => 16/787250 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 157 [patent_no_of_words] => 105235 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787250 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/787250
Humanized anti-PACAP antibodies Feb 10, 2020 Issued
Array ( [id] => 16743293 [patent_doc_number] => 10968268 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Humanized anti-PACAP antibodies [patent_app_type] => utility [patent_app_number] => 16/787313 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 157 [patent_no_of_words] => 105251 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787313 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/787313
Humanized anti-PACAP antibodies Feb 10, 2020 Issued
Array ( [id] => 16770896 [patent_doc_number] => 10981985 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Anti-PACAP antibodies [patent_app_type] => utility [patent_app_number] => 16/787294 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 96 [patent_no_of_words] => 56642 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787294 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/787294
Anti-PACAP antibodies Feb 10, 2020 Issued
Array ( [id] => 15963129 [patent_doc_number] => 20200165316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/787260 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787260 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/787260
Humanized anti-PACAP antibodies Feb 10, 2020 Issued
Array ( [id] => 18102465 [patent_doc_number] => 11542341 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Kit for detecting coronary artery disease comprising an MAA protein adduct and reagents that bind to antibodies [patent_app_type] => utility [patent_app_number] => 16/782015 [patent_app_country] => US [patent_app_date] => 2020-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 21093 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782015 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/782015
Kit for detecting coronary artery disease comprising an MAA protein adduct and reagents that bind to antibodies Feb 3, 2020 Issued
Array ( [id] => 16238608 [patent_doc_number] => 20200255842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => LONG-ACTING G-CSF FOR PREVENTING NEUTROPENIA OR REDUCING DURATION OF NEUTROPENIA [patent_app_type] => utility [patent_app_number] => 16/748057 [patent_app_country] => US [patent_app_date] => 2020-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22288 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 229 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16748057 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/748057
Long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia Jan 20, 2020 Issued
Array ( [id] => 17458780 [patent_doc_number] => 20220072084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => THERAPEUTIC NANOCONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/423549 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423549 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/423549
THERAPEUTIC NANOCONJUGATES AND USES THEREOF Jan 15, 2020 Pending
Array ( [id] => 17611548 [patent_doc_number] => 20220153827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis [patent_app_type] => utility [patent_app_number] => 17/423177 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423177 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/423177
Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis Jan 13, 2020 Pending
Array ( [id] => 16435726 [patent_doc_number] => 20200353051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => Chimeric Immunoreceptor Useful in Treating Human Cancers [patent_app_type] => utility [patent_app_number] => 16/723782 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16723782 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/723782
Chimeric immunoreceptor useful in treating human cancers Dec 19, 2019 Issued
Array ( [id] => 16206565 [patent_doc_number] => 20200239555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/714294 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714294 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/714294
Polynucleotides encoding anti-ApoC3 antibodies Dec 12, 2019 Issued
Menu